Imaxio
  • About Us
  • Our Products
  • Leptospirosis
  • News
  • Contact us

IMAXIO
News

2017

OSIVAX - June 2017
Creation of OSIVAX, a spin-off taking over IMAXIO's R&D activity, with a €2.7 million seed funding round


IMAXIO & DKFZ - April 2017
IMAXIO signs a license agreement with the German Cancer Research Center (DKFZ)

Influenza - March 2017
IMAXIO receives scientific advice from the EMA for its influenza vaccine candidate

2016

Trolovol® - December 2016
IMAXIO sells Trolovol in order to focus exclusively on vaccines


Leptospirosis - November 2016
Execution of a collaboration agreement with AJ Biologics to extend the commercialisation of IMAXIO's leptospirosis vaccine in Malaysia


Cancer - October 2016
Execution of a collaboration agreement with Centre Léon Bérard, and award of a grant from CLARA, for the preclinical development of an anticancer immunotherapy based on the oligoDOM® v1.0 technology

Intellectual property - May 2016
Receipt of notices of allowance from the USPTO for two new patent applications 

Tuberculosis - March 2016
Publication of the results of a phase I trial of MVA85A-oligoDOM® v1.0, the first human clinical trial using the oligoDOM® technology 

Malaria - January 2016
Publication of a new scientific article covering the use of the oligoDOM® technology


2015

Malaria - November 2015
Potential new vaccine candidate aims to block transmission of malaria parasites

Bellerophon project - June 2015

Call for process development and GMP manufacture of a vaccine candidate



2014

ANR grant - October 2014
France's National Research Agency (ANR) selects the OPTIVAC Project and contributes EUR 600,000 (USD 772,000) to improve the efficacy of influenza vaccines

IMAXIO & DKFZ - October 2014

IMAXIO signs an option for a license agreement with the German Cancer Research Center (DKFZ)



2013

IMAXIO & VitamFero - October 2013
IMAXIO and VitamFero launch a R&D collaboration

Sale of the genomics division - October 2013
IMAXIO sells its genomics division to Hybrigenics to focus on its immunology business


First human clinical trial of oligoDOM® v1.0 - September 2013
IMAXIO announces the first human clinical trial using its pro-immunogenic technology oligoDOM® v1.0, in tuberculosis


FP7 grant - July 2013
Bellerophon Project awarded EUR 5.5 million by EU to develop Staphylococcus aureus vaccine


oligoDOM® in animal health - June 2013
IMAXIO signs an option for a license agreement with a leading global animal health company to develop veterinary vaccines


Trolovol® - January 2013
IMAXIO acquires Trolovol, an orphan drug indicated for a congenital metabolic disease



2012

IMAXIO & Merial - December 2012
Signing of an option for a licence agrement to develop an animal health vaccine

Funding - April 2012

IMAXIO closes € 2.9-million funding round



Contact us
Legal mentions
En français
Proudly powered by Weebly
  • About Us
  • Our Products
  • Leptospirosis
  • News
  • Contact us